Geyer O, Lazar M, Novack G D, Shen D, Eto C Y
Department of Ophthalmology, Ichilove Medical Center, Sackler School of Medicine, University of Tel Aviv, Israel.
Br J Ophthalmol. 1988 Dec;72(12):892-6. doi: 10.1136/bjo.72.12.892.
Fifty-one patients with raised intraocular pressure (IOP) were treated for up to four years with one of three ophthalmic solutions: 0.5% levobunolol, 1% levobunolol, or 0.5% timolol. The study was conducted as a double-masked, randomised trial in which medications were administered twice daily to both eyes. Levobunolol and timolol were equally effective in reducing overall mean IOP; reductions were greater than 8.8 mmHg in all three treatment groups. The study showed levobunolol to be as safe and effective as timolol in the long-term control of raised IOP.
51名眼压升高的患者接受了三种眼科溶液之一的治疗，为期四年：0.5%左布诺洛尔、1%左布诺洛尔或0.5%噻吗洛尔。该研究作为一项双盲随机试验进行，药物每天给双眼各使用两次。左布诺洛尔和噻吗洛尔在降低总体平均眼压方面同样有效；所有三个治疗组的眼压降低均超过8.8 mmHg。该研究表明，在长期控制眼压升高方面，左布诺洛尔与噻吗洛尔一样安全有效。
